SDH-Engine — Drug Repurposing for SDH-Deficient Diseases

This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

13 candidates mapped to SDH-deficient disease pathways

All (65)established (7)clinical trial (13)preclinical (13)theoretical (32)

Pan-FGFR inhibitor (FGFR1/2/3/4)

Fgfr SignalingEpigenetic Dysregulation

Temodar, Temodal

Alkylating agent

Epigenetic Dysregulation

FDA Approved1 trial

Tazverik

EZH2 inhibitor (PRC2 inhibitor)

Epigenetic Dysregulation

FDA Approved1 trial

Lynparza

PARP inhibitor (PARP1/2)

Sdh Driven HrdOxidative Stress Ros

FDA Approved1 trial

CB-839

Glutaminase inhibitor

Glutamine Dependency

Afinitor

mTOR inhibitor (rapalog)

FDA Approved1 trial

Pemazyre

Selective FGFR1/2/3 inhibitor

FDA Approved1 trial

Yttrium-90 SIRT

SIR-Spheres, TheraSphere

Liver-directed radioembolization

POLQ inhibitor (DNA polymerase theta inhibitor)

Polq Tmej Backup RepairSdh Driven Hrd

[212Pb]VMT-α-NET

Alpha-particle SSTR2-targeted radioligand therapy (RLT)

Sstr2 Somatostatin VulnerabilitySdh Driven Hrd

Inobrodib

CBP/p300 bromodomain inhibitor

Cbp P300 Hat CoactivatorEpigenetic Dysregulation

AB928

Adenosine A2A/A2B receptor antagonist (dual; oral small molecule)

Hif Cd73 Adenosine ImmunosuppressionHif Pseudohypoxia

Hu5F9-G4

Anti-CD47 monoclonal antibody (macrophage phagocytosis-checkpoint inhibitor)

Hif Cd47 Phagocytosis EvasionHif Pseudohypoxia